Daxor Corporation Awarded Support from the National Institutes of Health (NIH) Catalyze Preclinical Services Program
04 Octubre 2023 - 7:00AM
Daxor Corporation (NASDAQ: DXR), the global leader in blood volume
measurement technology, today announces it has been accepted into
the National Institutes of Health (NIH) Catalyze Preclinical
Services Program. This program supports preclinical development,
including studies and activities needed to meet the regulatory
requirements for therapeutic and device submissions of technologies
relevant to the National Heart, Lung, and Blood Institute (NHLBI)’s
mission. This effort will be done in collaboration with two
nationally recognized contract research organizations, to support
the continued development of Daxor’s non-nuclear fluorescent blood
volume analyzer (BVA) device.
“This exciting initiative will facilitate a
tracer with practical applications in settings as diverse as a
doctor’s office to critical care units or even intraoperatively as
well. We are gratified to receive the valuable support of the NIH’s
Catalyze Program which recognizes the significant impact that this
technology will bring once commercialized. The capacity to improve
outcomes for millions of patients at multiple points within the
healthcare system is exactly the innovative work that fits within
the scope of the Catalyze Program and Daxor’s vision - optimal
blood for all,” said Michael Feldschuh, Daxor’s CEO and
President.
- The Catalyze Program is an
ultra-selective initiative to fund the most promising future
medical innovations by the NIH.
- The Catalyze Program is designed to
fund key preclinical research of technologies and transformative
platforms by NHLBI.
- Daxor will receive support and
direct funding from third-party labs to conduct needed preclinical
work toward an FDA submission of its next generation non-nuclear
tracer system.
- This initiative is separate from
the existing initiative to launch a next generation bedside
analyzer that is undergoing validation in preparation for an FDA
submission slated for before the end of 2023.
“We are honored to have been selected by the NIH
into their Catalyze Program to support the acceleration of our
non-nuclear tracer development efforts,” said Jonathan Feldschuh,
Chief Scientific Officer at Daxor. “Our non-nuclear blood volume
measurement device will be a state-of-the-art blood volume
diagnostic that will expand use of our test into even more clinical
settings and for more indications and will be designed to work on
our new point-of-care platform.”
More information about the Catalyze Program can
be found at https://nhlbicatalyze.org/.
About Daxor
Corporation
Daxor Corporation (NASDAQ: DXR), is the global
leader in blood volume measurement technology focused on blood
volume testing innovation. We developed and market the BVA-100®
(Blood Volume Analyzer), the only diagnostic blood test cleared by
the FDA to provide safe, accurate, objective quantification of
blood volume status and composition compared to patient-specific
norms. Over 65,000+ tests have been performed at leading hospital
centers across the U.S., enhancing hospital performance metrics in
a broad range of surgical and medical conditions, including
significantly reducing mortality and readmissions in heart failure
and critical care. Daxor has several ongoing trials in the areas of
heart failure treatment with support from the NIH and is under
contract developing analyzers to improve combat casualty care with
the U.S. Department of Defense. Daxor's mission is to advance
healthcare by enabling optimal fluid management with blood volume
analysis. Daxor’s vision is optimal blood volume for all. For more
information, please visit our website at Daxor.com. Sign up to
receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret ShapiroSr.
Managing Partner, CORE IR1-516-222-2560brets@coreir.com
Daxor (NASDAQ:DXR)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Daxor (NASDAQ:DXR)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024